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Abstract
Objective To evaluate the association between use of benzodiazepines
and incident dementia.
Design Prospective, population based study.
Setting PAQUID study, France.
Participants 1063 men and women (mean age 78.2 years) who were
free of dementia and did not start taking benzodiazepines until at least
the third year of follow-up.
Main outcomemeasures Incident dementia, confirmed by a neurologist.
Results During a 15 year follow-up, 253 incident cases of dementia
were confirmed. New use of benzodiazepines was associated with an
increased risk of dementia (multivariable adjusted hazard ratio 1.60,
95% confidence interval 1.08 to 2.38). Sensitivity analysis considering
the existence of depressive symptoms showed a similar association
(hazard ratio 1.62, 1.08 to 2.43). A secondary analysis pooled cohorts
of participants who started benzodiazepines during follow-up and
evaluated the association with incident dementia. The pooled hazard
ratio across the five cohorts of new benzodiazepine users was 1.46 (1.10
to 1.94). Results of a complementary nested case-control study showed
that ever use of benzodiazepines was associated with an approximately
50% increase in the risk of dementia (adjusted odds ratio 1.55, 1.24 to
1.95) compared with never users. The results were similar in past users
(odds ratio 1.56, 1.23 to 1.98) and recent users (1.48, 0.83 to 2.63) but
reached significance only for past users.
Conclusions In this prospective population based study, new use of
benzodiazepines was associated with increased risk of dementia. The
result was robust in pooled analyses across cohorts of new users of
benzodiazepines throughout the study and in a complementary
case-control study. Considering the extent to which benzodiazepines
are prescribed and the number of potential adverse effects of this drug
class in the general population, indiscriminate widespread use should
be cautioned against.
Introduction
Primarily indicated for treating the symptoms of anxiety and
sleep disorders over short periods,1 benzodiazepines are widely
prescribed in developed countries.2 3 In France, 30% of people
aged 65 years and over use benzodiazepines.4 They are used by
more than 20% of people aged 65 and over in Canada and Spain
and by around 15% of those in Australia.5-7Benzodiazepine use
is less widespread but still high in elderly people in the United
States and the United Kingdom.8 9 Consumption of
benzodiazepines is often chronic,2 10 and many people take them
for years despite the existence of good practice guidelines
suggesting that the duration should be limited to a few
weeks.1 10-12
The short term effects of benzodiazepines on cognition are well
known.13-16 They are mediated through an agonist action on
receptors of γ aminobutyric acid A, a major inhibitory
neurotransmitter in the brain. However, the long term adverse
effects of benzodiazepines on cognition are still debated.
Studies focusing on the association between benzodiazepine
use and dementia or cognitive decline in elderly people have
shown conflicting results.17 Some found an increased risk of
dementia or cognitive impairment in benzodiazepine users,9 18-21
whereas others were not conclusive or reported a potential
protective effect.22-27 In previous studies, the timing of exposure
to benzodiazepines in relation to the outcome event allowed for
the possibility of reverse causation. Insomnia, depression, and
anxiety (the main indications for prescribing benzodiazepines)
can be prodromal symptoms of dementia.28
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Dementia is already responsible for a major societal burden
worldwide.With more than 81million cases expected in 2040,29
this burden will become even greater in the coming decades.30
As treatment options remain limited, identifying factors
contributing to dementia is critical. The objective of this study
was to assess the association between starting benzodiazepines
and risk of subsequent dementia in a well defined population
based cohort of elderly people with available follow-up of up
to 20 years.
Methods
Participants, design, and settings
We studied participants in the prospective PAQUID cohort
study, which assesses normal and pathological brain ageing. Its
methods and design have been described in detail elsewhere.31
Briefly, a representative sample of 3777 community dwelling
people aged 65 years and over between 1987 and 1989 were
randomly selected from the general population of the Gironde
and Dordogne, two administrative areas in southwest France.31
Follow-up visits took place every two or three years, and
information up to the 20 year visit is available. At baseline and
at each follow-up visit, trained neuropsychologists collected
detailed information on personal characteristics,
sociodemographics, life habits, health conditions, drug use,
functional abilities, depressive symptoms, and cognition during
face to face interviews.
In the study reported here, we used a cohort and a nested
case-control study design. In the cohort (main) analysis, we
introduced an observation period of three to five years before
the start of follow-up. People were eligible to participate if they
were free from dementia at the five year follow-up visit (T5)
and reported use of benzodiazepines for the first time on that
date (fig 1⇓). Thus, participants did not use benzodiazepines at
least up to the three year follow-up visit. This period was
essential to allow adjustment for factors associated with starting
benzodiazepines, including cognitive decline from inclusion in
the PAQUID study (T0) to the three year follow-up visit, allaying
concerns about confounding by indication, and to limit and
assess the possibility of a reverse causation that was suspected
in previously published studies. In the nested case-control study,
we included all eligible participants in the PAQUID study.
Exposure definition and measurement
Data on drug use, including benzodiazepine use, were collected
with a standardised questionnaire at each follow-up visit. In
addition, participants or their usual caregivers were asked about
prescribed and non-prescribed drugs used regularly during the
previous two weeks. The interviewer then validated drug use
by visual inspection of the participant’s medicine packs. The
neuropsychologists who carried out the face to face interviews
were unaware of the hypothesis of our study.
We classified all eligible participants as new benzodiazepine
users or non-users according to ascertainment of exposure at T5
(fig 1⇓). The exposure group comprised participants without
declared benzodiazepine use at T0 and T3 and declaration of use
at T5, so they constituted new users of benzodiazepines between
T3 and T5. In the main analysis, we did not consider subsequent
exposure to benzodiazepines when estimating the association
between benzodiazepine use and occurrence of dementia.
Participants without any declared use at T0, T3, and T5 served
as the reference group.
We considered all benzodiazepines and similar drugs available
in France between 1988 and 2006 (alprazolam, bromazepam,
chlordiazepoxide, clobazam, clonazepam, clorazepate,
clotiazepam, diazepam, estazolam, flunitrazepam, loflazepate,
loprazolam, lormetazepam, nitrazepam, nordazepam, prazepam,
oxazepam, temazepam, tetrazepam, tofizopam, triazolam,
zolpidem, and zopiclone).
Outcome definition and measurement
At each follow-up, trained psychologists systematically assessed
dementia on the basis of the Diagnostic and Statistical Manual
of Mental Disorders, third edition, revised (DSM-III-R).
Neurologists further examined suspected cases to confirm the
diagnosis; our main outcome was neurologist confirmed
dementia. As the follow-up visits were two or three years apart,
we assigned the midpoint of the time interval between two
follow-up visits as the index date for dementia. We determined
incident cases of dementia by using information from the eight
year follow-up visit (T8), indicating any new occurrence of
dementia after baseline (T5).
Covariates
In addition to age and sex, which are risk factors both for
benzodiazepine use and for dementia, the covariates used for
adjustment at the baseline for this study (T5) included factors
considered to be associated with both benzodiazepine use and
risk of dementia32 33: educational level (schooling duration ≥7
years v <7 years), marital status (single or not), wine
consumption (regular consumption v no consumption), existence
of diabetes mellitus or high blood pressure (defined according
to patients’ use of antidiabetic agents or antihypertensive drugs
at study baseline (T5)), use of statins, use of platelet inhibitors
or oral anticoagulants, and cognitive decline. For cognitive
decline, three different tests were considered: the mini-mental
state examination,34 the Benton visual retention test,35 and the
Isaacs set test.36 For these three tests, we considered the
difference between the scores obtained at T3 and at T0 (inclusion
in the PAQUID study) as a quantitative variable. Depressive
symptoms were assessed by using the Center for Epidemiologic
Studies depression scale,37 categorised according to the threshold
validated for the French population with a cut-off score of ≥17
for men and ≥23 for women,38 defining the presence of
significant depressive symptoms.
Statistical analysis
Cohort, main analysis
We compared the characteristics of new users of
benzodiazepines with those of non-users by using numbers and
percentages for qualitative variables and median and
interquartile range for quantitative variables. Figure 1⇓ details
the follow-up scheme and design.
We used Kaplan-Meier curves and log-rank tests for univariable
dementia-free survival analyses in exposed and non-exposed
groups. We used multivariable adjusted Cox proportional
hazards models to evaluate the association between new use
(starting between T3 and T5) of benzodiazepines and risk of
incident dementia, adjusting for potential confounding factors.
The dependent variable was the occurrence of incident dementia.
We adjusted the models for the following potential confounding
factors (covariates): age, sex, education level, marital status,
regular wine consumption, change in the mini-mental state
examination between T0 and T3, and use of antidiabetic agents,
antihypertensive drugs, statins, and platelet inhibitors or oral
anticoagulants. As depression is thought to be a potential
prodromal symptom of dementia,39 40 we did not consider
depressive symptoms as a potential confounder in our main
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analysis. However, we included information on the presence of
depressive symptoms in a sensitivity analysis because depression
has also been described as a risk factor for dementia.41 We
calculated person time from the date of the PAQUID five year
follow-up visit (baseline of our study) to the estimated date of
dementia, death, or loss to follow-up or the date of the 20 year
follow-up visit, whichever came first. We verified the
proportionality assumption of the Cox model by evaluating
Cox-Snell residuals and found no violation.
We evaluated whether the association between benzodiazepine
use and dementia was modified by age (80-84 or ≥85 v 70-79
years), sex, or schooling duration (≥7 v <7 years). To test for
statistical significant effect modification, we used the likelihood
ratio test contrasting the main model with a model including
appropriate interaction terms.
Cohort, secondary analysis
To account for potential time varying effects on the association
between benzodiazepine use and risk of dementia, we considered
new cohorts of benzodiazepines users between the baseline of
our study (PAQUID T5) and the following 15 years of follow-up
(PAQUID T8 to T20) in a second analysis. We chose this
approach as we believe that a Cox model updating information
on exposure would not allow for a correct causal inference
structure.42 At “baseline” and each of the four follow-up time
points (T8, T10, T13, and T15), we created cohorts of new users
(participants reporting benzodiazepine use for the first time at
the specific follow-up visit) and followed each cohort until a
censoring event occurred or until the end of the study, whichever
came first. We then evaluated the association of each of these
cohorts with the risk of subsequent dementia compared with
participants who did not start benzodiazepines at a given time
point, adjusting for the above mentioned confounders including
information on depressive symptoms. The information on
confounders was updated to the respective follow-up time point.
Finally, we pooled the five cohorts by using a fixed effect model.
Nested case-control analysis
Participants still followed at T8, without dementia before this
date and with an accurate date of diagnosis of dementia, were
eligible for a nested case-control analysis in the PAQUID cohort.
We defined cases as participants with an incident diagnosis of
dementia fromT8 onwards, as in the cohort study.We considered
all participants without a diagnosis of dementia at the time point
when a case was diagnosed (index date) as controls. Among
these, we randomly selected up to four controls and matched
them with each case by age (±2 years) and sex. Participants
could be used as controls for cases and later selected as cases
if they presented with an incident diagnosis of dementia
(incidence density sampling).
For the nested case-control study, we did not exclude any
prevalent benzodiazepine exposure. We first classified
participants as ever users (if at least one use of benzodiazepine
was declared before the index date) and never users (no
declaration of benzodiazepine use before index date). Among
ever users, we then identified recent users (reported use at the
follow-up visit preceding the index date but never before) and
past users (reported use at least three visits before the index date
or earlier).
We used conditional logistic regression to evaluate the
association between benzodiazepine use and risk of dementia.
We built two series of models, each considering one of the
definitions retained for exposure to benzodiazepines. We did
analyses using similar adjustment to that used for the main
cohort analysis, including depressive symptoms. Models not
including information on depressive symptoms showed similar
associations. Potential confounding variables were measured at
three follow-up time points (seven or eight years) before the
index date.
We used the SAS statistical package (SAS 9.3 for Windows)
for all analyses. All reported P values are two tailed, and we
considered P<0.05 to be statistically significant.
Results
Cohort analysis
Population
Of the 3777 participants in the PAQUID study, 2084 were still
in active follow-up at the five year visit (T5, baseline for this
study). We excluded 154 participants with prevalent dementia
at the five year follow-up visit, 735 participants with a history
of benzodiazepine use or prevalent use, and 132 with missing
or questionable information on history of benzodiazepine use.
The sample thus included 1063 participants free of dementia at
T5 and without prevalent use of benzodiazepines up until T3 (fig
2⇓). Among the 1063 eligible participants, 95 (8.9%) reported
consumption of a benzodiazepine at study baseline (T5),
indicating new use between T3 and T5. Table 1⇓ shows
characteristics of participants included in the analysis according
to benzodiazepine exposure status. Compared with non-users
(n=968), new users of benzodiazepines (n=95) were more likely
to have shorter school duration (66% v 77% with duration ≥7
years), to be single or widowed (52% v 41%), to have more
significant depressive symptoms (16% v 4%), to use
antihypertensive drugs (74% v 58%), and to use platelet
inhibitors or oral anticoagulants (15% v 6%) and consumed
wine less regularly (63% v 73%). No difference existed between
new users of benzodiazepines and non-users in terms of age,
sex, diabetes mellitus, statin use, and cognitive evolution
between inclusion in the PAQUID study (T0) and the three year
follow-up visit (T3).
Main analysis
During the 15 year follow-up (median 6.2 (interquartile range
2.6-12.3) years), 253 (23.8%) cases of dementia were
confirmed—30 (32%) in benzodiazepine users and 223 (23.0%)
in non-users. Compared with non-use, new use of
benzodiazepines between T3 and T5was associated with a shorter
dementia-free survival in the study population (crude survival
analysis, log-rank test P=0.03) (fig 3⇓). The incidence rate of
dementia during the 15 year follow-up was 4.8 per 100 person
years in the exposed group compared with 3.2 per 100 person
years in the non-exposed group. Compared with participants
who did not report use of benzodiazepines at baseline (n=968),
starting benzodiazepines between T3 and T5 (n=95) was
associated with a significantly increased risk of dementia (hazard
ratio 1.60, 95% confidence interval 1.08 to 2.38), after
adjustment for potential confounding factors. When further
adjusted for depressive symptoms, this result was unchanged
(hazard ratio 1.62, 1.08 to 2.43) (table 2⇓). Use of the Isaacs or
the Benton test instead of the mini-mental state examination
yielded similar results (hazard ratios 1.67 and 1.68).
Out of the 1063 participants included, 57 (5%) had missing
values for at least one of the 10 variables used for adjustment
in the main analysis—8 (8%) in the exposed group and 49 (5%)
in the non-exposed group (P=0.17). We did not find any
significant effect modification of the association between
starting benzodiazepines and incident dementia by age (P for
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interaction=0.10), sex (P for interaction=0.23), or duration of
schooling (P for interaction=0.43).
Secondary analysis
In the secondary analysis, we created benzodiazepine new user
and non-user cohorts at baseline (T5) and the follow-up time
points T8, T10, T13, and T15. This added a total of 116 new users
during follow-up to the 95 new users at baseline.We then pooled
the association between new use of benzodiazepine and risk of
incident dementia across the five cohorts (baseline and four
follow-up cohorts) by using a fixed effect model. The pooled
multivariable adjusted hazard ratio of dementia was 1.40 (1.06
to 1.85). Additional control for symptoms of depression did not
alter this result (hazard ratio 1.46, 1.10 to 1.94) (fig 4⇓).
Nested case-control analysis
One thousand six hundred and thirty-three participants still
followed at T8were eligible for the nested case-control analysis
(fig 5⇓).We identified 467 cases of dementia and 1810 controls
for the nested case-control analysis (which did not exclude
prevalent users at T0 or T3, unlike in the cohort analysis). Table
3⇓ shows characteristics of cases and controls. Ever users had
an increased risk of dementia (adjusted odds ratio 1.55, 1.24 to
1.95). We found similar associations in past users (adjusted
odds ratio 1.56, 1.23 to 1.98) and recent users (adjusted odds
ratio 1.48, 0.83 to 2.63), but the result was significant only for
past users (table 4⇓).
Discussion
In this large, prospective, population based study of elderly
people who were free of dementia and did not use
benzodiazepines until at least the third year of follow-up, new
use of benzodiazepines was associated with a significant,
approximately 50% increase in the risk of dementia. This result
remained stable after adjustment for potential confounding
factors, including cognitive decline before starting
benzodiazepine and clinically significant symptoms of
depression. It also remained robust when we pooled five cohorts
of new benzodiazepine users throughout the 15 year follow-up
period and in a complementary nested case-control study.
Comparison with other studies
Our findings are consistent with three previous case-control
studies that also showed an increased risk of dementia in
benzodiazepine users. Two of them were done in Taiwan using
health insurance data of people aged 45 years and older and
found an increased risk of dementia in chronic users (>6months)
(adjusted odds ratio 1.24, 1.01 to 1.53)18 and current users
(adjusted odds ratio 2.71, 2.46 to 2.99).19 A nested case-control
study among French people aged 65 and over showed an
increased risk of dementia in former users (adjusted odds ratio
2.3, 1.2 to 4.5).21 However, the maximum length of follow-up
in those studies was eight years,18 19 21 raising concerns that
prodomal symptoms of dementia could have influenced
benzodiazepine use.28 The results of the Caerphilly prospective
cohort showed an increase in the risk of dementia in people who
ever used benzodiazepines (adjusted odds ratio 2.94, 1.16 to
7.46) up to 22 years of follow-up. The results of that study also
suggested that the potential excess risk of dementia associated
with benzodiazepine use may apply to a population with low
benzodiazepine consumption. However, benzodiazepine users
could not be classified as new starters and the sample size was
too small to allow for meaningful subgroup analyses (for
example, 12 participants had exposure of four years or more
among the 93 with dementia).9
In contrast to our results, two studies did not find an increased
risk of dementia among elderly people using benzodiazepines.
The results of one (case-control) study, however, showed a
similar effect estimate to ours, but this did not reach statistical
significance (adjusted odds ratio 1.5, 0.6 to 3.4), probably owing
to the small sample size.22 The other (cohort) study, suggested
a beneficial effect of benzodiazepine use on dementia
(unadjusted odds ratio 0.34) but considered past users as
members of the reference group, which could have biased the
results.27 A more detailed comparison of studies that have
explored the potential association between benzodiazepine use
and the risk of dementia is summarised in the supplementary
(web extra) table.
Our study included a markedly larger number of participants
than did the previous long term study on the topic,9 and we
incorporated a run-in time of at least three years to allow
adjustment for factors associated with starting benzodiazepines,
thereby reducing the possibility of reverse causation. In that
sense, an excess risk observed during the early phase of exposure
could be congruent with a reverse causation bias, which would
not be the case if the increase in risk appeared long after the
start of exposure.
Benzodiazepines could also be seen as an early risk marker for
dementia that might highlight a particular at risk background
in patients, but without playing any causal role in the occurrence
of the disease. For example, persistent anxiety in middle age
has been shown to be associated with a greater risk of dementia
in elderly people.43Hence, benzodiazepine use may be a marker
of this scenario and might help to identify people at increased
risk of, and not already on the causal pathway leading to,
dementia. However, in our study, two observations argue against
this hypothesis: the strength of association did not increase
across the five cohorts of new users (which would be expected
in the event of reverse causation, as the time from
benzodiazepine use to development of dementia is shorter), and
the association between new use of benzodiazepines and
dementia increased after about seven years of follow-up (fig
3⇓). However, reverse causation cannot be entirely ruled out as
an alternative explanation of our findings.
Strengths and limitations
This study has several strengths. Firstly, it was based on a long
follow-up period allowing assessment of the delayed effects of
exposure to benzodiazepine, which was not possible in previous
studies (except one9). Secondly, we defined incident dementia
by applying validated criteria (DSM-III-R) ascertained by senior
neurologists who were blind to the study hypothesis. Thirdly,
trained interviewers prospectively recorded and validated data
on drug exposure by visual inspection of the patients’ medicine.
Fourthly, restricting analyses to new users of benzodiazepine
after at least a three to five year “run-in” period allowed us to
adjust for factors strongly associated with starting
benzodiazepines. Lastly, the study was carried out in a large
representative cohort of elderly participants,31 with adjustment
on a large number of potential confounders of the
benzodiazepine-dementia association.2 3 32 33
The study also has several limitations. Firstly, we had a limited
number of new users at baseline (n=95), thereby limiting the
power for subgroup analyses and ruling out the possibility of
assessing individual benzodiazepines. However, the literature
contains no suggestion that specific benzodiazepines have
differential effects on cognition or dementia.23 Secondly, we
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could not adjust separately for anxiety and sleep disorders, both
putative dementia prodromes, owing to the lack of specific
measurement of these symptoms in the PAQUID programme.
However, the Center for Epidemiologic Studies depression scale
includes these items in computation of its global score, and
entering three separate scores in the model could have raised a
concern about colinearity, as depressive symptoms are often
associated with sleep disorders and anxiety, especially in elderly
people. Lastly, people who had missing information for
benzodiazepine use during the three to five year run-in period
of this study were not included, as they could not be ascertained
for exposure status. As these missing data were linked to
unperformed follow-up, which has been related to subsequent
higher risk of dementia,44 a potential selection bias could have
occurred. However, these ineligible participants had a lower
schooling level and were more likely to live alone, two factors
known to increase the risk of both benzodiazepine use and
incident dementia. Therefore, a potential selection bias due to
exclusion of people with missing information for exposure
before the index date would have tended to decrease the strength
of the association. The disparity in the incidence of dementia
over a comparable time window was similar to that seen in the
participants included.
Implication for clinical practice and public
health
Benzodiazepines remain useful for the treatment of acute anxiety
states and transient insomnia.45 46However, increasing evidence
shows that their use may induce adverse outcomes, mainly in
elderly people, such as serious falls and fall related fractures.47 48
Our data add to the accumulating evidence that use of
benzodiazepines is associated with increased risk of dementia,
which, given the high and often chronic consumption of these
drugs in many countries,10 49 50 would constitute a substantial
public health concern. Therefore, physicians should carefully
assess the expected benefits of the use of benzodiazepines in
the light of these adverse effects and, whenever possible, limit
prescription to a few weeks as recommended by the good
practice guidelines.1 In particular, uncontrolled chronic use of
benzodiazepines in elderly people should be cautioned against.
Unanswered questions and future research
Further research should explore whether long term use of
benzodiazepines in people under 65 is also associated with an
increased risk of dementia and should study possible correlations
between dosage or cumulative length of exposure and dementia.
Conclusion
The findings of this large prospective population based study
show that new use of benzodiazepines is associated with an
approximately 50% increase in the risk of dementia. The results
remained robust after control for potential confounders, in
pooled analysis across the follow-up time, and in a nested
case-control study. Considering the extent to which
benzodiazepines are now prescribed, physicians and regulatory
agencies should consider the increasing evidence of the potential
adverse effects of this drug class for the general population.
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Tables
Table 1| Baseline characteristics of participants from PAQUID study included in cohort analysis, according to benzodiazepine use. Values
are numbers (percentages) unless stated otherwise
Benzodiazepine non-users (n=968)Benzodiazepine new users (n=95)Characteristics
6.2 (2.6-12.5)6.1 (2.2-10.4)Median (interquartile range) follow-up (years)
223 (23.0)30 (32)Dementia*
474 (49.0)54 (57)Female sex
Age (years):
385 (39.8)35 (37)70-79
240 (24.8)26 (27)80-84
343 (35.4)34 (36)≥85
745 (77.0)63 (66)Schooling duration ≥7 years
394 (40.7)49 (52)Single or widowed
680/932 (73.0)57/90 (63)Wine consumption
38/944 (4.0)15/93 (16)Significant depressive symptoms†
562 (58.1)70 (74)High blood pressure‡
81 (8.4)7 (7)Diabetes mellitus§
36 (3.7)5 (5)Statin use
55 (5.7)14 (15)Platelet inhibitor or oral anticoagulant use
Median (interquartile range) cognitive evolution trend:
0 (−1-1)0 (−1-1)MMSE score difference between T3 and T0
0 (−3-3)0 (−2-3)Isaacs score difference between T3 and T0
0 (−1-2)0 (−2-1)Benton score difference between T3 and T0
MMSE=mini-mental state examination.
*According to Diagnostic and Statistical Manual of Mental Disorders, third edition, revised criteria.
†Based on Center for Epidemiologic Studies depression scale (score ≥17 for men; ≥23 for women).
‡According to use of antihypertensive drugs.
§According to use of antidiabetic agents.
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Table 2| Association between new use of benzodiazepine with incident dementia in PAQUID study. Values are numbers (percentages)
unless stated otherwise
Hazard ratio (95%CI)No dementia during follow-upIncident dementia
(n=810)(n=253)Analysis adjusted for age*
1.00745 (92.0)223 (88)Benzodiazepine non-users
1.59 (1.09 to 2.34)65 (8.0)30 (12)Benzodiazepine new users
(n=766)(n=240)Main analysis†
1.00708 (92.4)211 (88)Benzodiazepine non-users
1.60 (1.08 to 2.38)58 (7.6)29 (12)Benzodiazepine new users
(n=752)(n=231)Complementary analysis†‡
1.00695 (92.4)203 (88)Benzodiazepine non-users
1.62 (1.08 to 2.43)57 (7.6)28 (12)Benzodiazepine new users
*At baseline (T5).
†Adjusted for age, sex, schooling duration, singleness, wine consumption, use of antihypertensive drugs, use of antidiabetic agents, use of statins, use of platelet
inhibitors or oral anticoagulants, and mini-mental state examination evolution between inclusion (T0) and three year follow-up visit (T3).
‡Adjusted for significant depressive symptoms according Center for Epidemiologic Studies depression scale (score ≥17 for men; ≥23 for women) at baseline (T5).
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Table 3| Characteristics of cases and controls included in nested case-control study from PAQUID study. Values are numbers (percentages)
Controls (n=1810)Cases (n=467)Characteristics
741 (40.9)233 (50)Benzodiazepine ever users
52 (2.9)17 (4)Benzodiazepine recent users
689 (38.1)216 (46)Benzodiazepine past users
1339 (74.0)298 (64)Schooling duration ≥7 years
1012/1784 (56.7)240/456 (53)Single or widowed
1066/1777 (60.0)267/454 (59)Wine consumption
153/1778 (8.6)46/450 (10)Significant depressive symptoms*
1125/1784 (63.1)274/456 (60)High blood pressure†
96/1784 (5.4)29/456 (6)Diabetes mellitus‡
73/1784 (4.1)26/456 (6)Statin use
164/1784 (9.2)32/456 (7)Platelet inhibitor or oral anticoagulant use
*Based on Center for Epidemiologic Studies depression scale (score ≥17 for men; ≥23 for women).
†According to use of antihypertensive drugs.
‡According to use of antidiabetic agents.
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Table 4| Risk of dementia associated with benzodiazepine use in nested case control study of 1633 elderly people form PAQUID study.
Values are numbers (percentages) unless stated otherwise
Odds ratio (95%CI) by drug useControlsCases
Ever use analysis
(n=1810)(n=467)Univariate analysis*:
1.00845 (46.7)175 (37)Benzodiazepine non-users
1.54 (1.24 to 1.93)741 (40.9)233 (50)Benzodiazepine ever users
1.30 (0.93 to 1.81)224 (12.4)59 (13)Missing exposure
(n=1771)(n=449)Multivariable analysis*†:
1.00844 (47.7)174 (39)Benzodiazepine non-users
1.55 (1.24 to 1.95)738 (41.7)233 (52)Benzodiazepine ever users
1.04 (0.71 to 1.53)189 (10.7)42 (9)Missing exposure
Recent/past use analysis
(n=1810)(n=467)Univariate analysis*:
1.00845 (46.7)175 (37)Benzodiazepine non-users
1.58 (0.90 to 2.78)52 (2.9)17 (4)Benzodiazepine recent users
1.54 (1.23 to 1.93)689 (38.1)216 (46)Benzodiazepine past users
1.30 (0.93 to 1.81)224 (12.4)59 (13)Missing exposure
(n=1771)(n=449)Multivariable analysis*†:
1.00844 (47.7)174 (39)Benzodiazepine non-users
1.48 (0.83 to 2.63)52 (2.9)17 (4)Benzodiazepine recent users
1.56 (1.23 to 1.98)686 (38.7)216 (48)Benzodiazepine past users
1.04 (0.71 to 1.53)189 (10.7)42 (9)Missing exposure
*Matched for age and sex.
†Adjusted for schooling duration, singleness, wine consumption, use of antihypertensive drugs, use of antidiabetic agents, use of statins, use of platelet inhibitors
or oral anticoagulants, and significant depressive symptoms according to Center for Epidemiologic Studies depression scale (score ≥17 for men; ≥23 for women),
7 or 8 years before index date.
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Figures
Fig 1 Follow-up scheme and study design for primary cohort analysis
Fig 2 Identification of participants from PAQUID study followed up at T5 (follow-up at year 5 of PAQUID study) and eligible
for main cohort analysis (no dementia and no prevalent benzodiazepine use)
Fig 3 Dementia-free survival in PAQUID study, in new benzodiazepine users and non-users at baseline (T5)
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Fig 4 Pooled associations between new benzodiazepine use at follow-up years 5 (cohort T5), 8 (cohort T8), 10 (cohort T10),
13 (cohort T13), and 15 (cohort T15) and risk of subsequent dementia. Results adjusted for age, sex, schooling duration,
singleness, wine consumption, use of antihypertensive drugs, use of antidiabetic agents, use of statins, use of platelet
inhibitors or oral anticoagulants, depressive symptoms, and mini-mental state examination evolution between inclusion (T0)
and 3 year follow-up visit (T3)
Fig 5 Identification of participants from PAQUID study eligible for nested case-control analysis
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